GLP-1 Weight Loss: A Physician's Guide to Semaglutide, Tirzepatide, and What Actually Works

GLP-1 is a hormone released by your intestines when you eat. It does three things: it tells your pancreas to release insulin, tells your liver to stop dumping glucose, and tells your brain you're full. The problem is that natural GLP-1 breaks down in minutes. Semaglutide and tirzepatide are synthetic versions engineered to last a week.

When you inject a GLP-1 receptor agonist, you're essentially extending that post-meal satiety signal around the clock. Patients describe it as "the food noise turning off"—the constant mental negotiation about eating simply quiets. You feel full sooner, stay full longer, and don't experience the same reward response from hyper-palatable foods.

Tirzepatide is a dual agonist: it hits both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, which is why the weight loss data skews slightly higher—around 20–22% in the SURMOUNT trials versus 15–17% for semaglutide in the STEP trials. Both are once-weekly subcutaneous injections. Both require dose titration over 16–20 weeks to minimize nausea.

In our practice, we see the most success when patients understand they're not taking a diet pill. These medications reset the biological set point your body defends. That's why, when stopped abruptly, most patients regain weight—your body's regulatory system hasn't permanently changed.

The FDA-approved indications are clear: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea). But the real question is whether GLP-1 therapy fits your metabolic picture.

You're likely a good candidate if:

• You've lost weight before but regained it despite sustained effort
• You have visceral adiposity (belly fat) and early metabolic dysfunction—fasting insulin >10 µIU/mL, HbA1c 5.7–6.4%, elevated triglycerides
• You have a family history of type 2 diabetes and are in the pre-diabetic range
• Your weight is driving other risk factors: blood pressure creeping up, liver fat accumulating, joint pain worsening

You're probably not a good candidate if:

• You have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome (absolute contraindication)
• You have active gallbladder disease or a history of pancreatitis
• You're looking for a quick fix before a vacation—these are long-term metabolic tools, not event-driven interventions
• You haven't addressed foundational sleep, stress, or protein intake (medication works best layered on top of solid fundamentals)

In our Chicago-area practice, the typical patient is a 45-year-old professional who exercises regularly, eats reasonably well, but has slowly gained 30–40 pounds since their mid-30s and can't move the needle despite effort. That's the metabolic phenotype where GLP-1 therapy shines.

Both medications are effective. The choice often comes down to insurance coverage, cost, and individual tolerance. Here's how they compare:

Factor	Semaglutide (Wegovy/Ozempic)	Tirzepatide (Zepbound/Mounjaro)
Mechanism	GLP-1 agonist	GLP-1 + GIP dual agonist
Average weight loss	15–17% at 68 weeks	20–22% at 72 weeks
Dosing schedule	Weekly injection	Weekly injection
Maintenance dose	2.4 mg	10–15 mg
Nausea rate	~40% (mostly mild, early)	~30% (slightly better tolerated)
Cost (list price)	~$1,300/month	~$1,000–1,200/month
Compounded availability	Yes (semaglutide widely compounded)	Yes (tirzepatide increasingly available)

We typically start with whichever medication insurance covers or, if paying out-of-pocket, whichever compounded option offers the best quality assurance. Compounded GLP-1s are not FDA-approved finished products—they're prepared by 503A or 503B pharmacies during shortage periods. We only work with pharmacies that provide third-party testing certificates and source pharmaceutical-grade active ingredients.

If a patient plateaus on semaglutide, switching to tirzepatide often restarts weight loss due to the additional GIP activity. The reverse is less commonly needed.

The most common side effects are gastrointestinal: nausea, constipation, occasional diarrhea, and reflux. These peak during dose escalation and usually resolve within 2–4 weeks at each new dose.

What we do in practice:

• Slow the titration. If nausea is significant, stay at the current dose another 4 weeks before advancing.
• Optimize meal timing. Eat smaller, protein-forward meals. Avoid large, fatty, or late-night meals.
• Manage constipation proactively. Magnesium citrate 400–600 mg daily, adequate hydration, and fiber prevent the misery of severe constipation.
• Monitor for gallbladder issues. Rapid weight loss increases gallstone risk. If you develop right upper quadrant pain, we image.

Plateaus are nearly universal around month 6–9. Weight loss slows or stops even though you're on a therapeutic dose. This isn't failure—it's biology. Your body downregulates energy expenditure as you lose weight (adaptive thermogenesis).

To push through:

1. Reassess protein intake. Target 1.0–1.2 g per pound of ideal body weight to preserve lean mass.
2. Add or intensify resistance training. Muscle is metabolically active tissue; losing it worsens plateaus.
3. Consider dose optimization. Some patients benefit from the higher end of the dosing range or switching molecules.
4. Rule out other factors. Sleep deprivation, uncontrolled stress, and certain medications (e.g., beta-blockers, antipsychotics) blunt weight loss.

We don't chase the scale week-to-week. We track body composition via DEXA, waist circumference, and metabolic markers—HbA1c, fasting insulin, liver enzymes, lipid panels. Often the scale stalls while visceral fat and metabolic risk continue to improve.

Not every prescriber approaches GLP-1 therapy the same way. If you're considering treatment, here's the framework we use—and what you should expect from your physician:

1. Baseline labs and imaging At minimum: comprehensive metabolic panel, lipid panel, HbA1c, TSH, and liver function tests. We also check fasting insulin and consider a DEXA scan to establish baseline body composition. If there's concern for fatty liver, an ultrasound or FibroScan is helpful.

2. Contraindication screening Your doctor should explicitly ask about personal or family history of medullary thyroid cancer, MEN2 syndrome, pancreatitis, and gastroparesis. If you've had bariatric surgery, GLP-1s are still an option but require closer monitoring.

3. A clear titration plan You should leave the visit knowing your starting dose, escalation schedule, and what symptoms warrant slowing down or pausing. Cookie-cutter protocols don't work for everyone.

4. Long-term strategy Are you planning to stay on this medication indefinitely? Taper after goal weight? Transition to a lower maintenance dose? The data strongly suggest that stopping GLP-1 therapy leads to weight regain in most patients, so this should be a transparent conversation up front.

5. Cost and access Brand-name GLP-1s run $1,000–1,400/month without insurance. Many insurers cover them for diabetes (Ozempic, Mounjaro) but not weight loss (Wegovy, Zepbound), even if it's the same molecule. Compounded versions cost $200–400/month but come with trade-offs in regulatory oversight. Your physician should help you navigate this honestly.

If your doctor hands you a prescription without discussing these five domains, you're not getting a Medicine 3.0 approach—you're getting a transactional service.

We don't prescribe GLP-1 medications to help patients fit into smaller jeans. We prescribe them to reduce the cumulative burden of metabolic disease—the single largest driver of morbidity and mortality in our patient population.

Excess visceral adiposity increases your risk of:

• Cardiovascular disease via chronic inflammation, insulin resistance, and atherogenic dyslipidemia (high ApoB, small dense LDL)
• Type 2 diabetes and its downstream complications—neuropathy, retinopathy, nephropathy
• Fatty liver disease progressing to fibrosis and cirrhosis
• Obstructive sleep apnea worsening metabolic and cardiovascular risk in a vicious cycle
• Certain cancers (endometrial, breast, colon, kidney) linked to hyperinsulinemia and chronic inflammation

GLP-1 therapy, when used appropriately, doesn't just lower the number on the scale. It improves HbA1c, reduces liver fat, lowers blood pressure, improves lipid profiles, and in cardiovascular outcomes trials (SELECT, for example), reduces major adverse cardiovascular events by ~20%.

That's why we view these medications as metabolic tools, not cosmetic ones. The goal is to extend healthspan—the number of years you remain functional, energetic, and free of chronic disease—not just lifespan. If losing 15% of your body weight means you avoid diabetes, come off blood pressure medication, and reduce your 10-year ASCVD risk by half, that's a win worth pursuing.

But medication is never the whole story. We layer GLP-1 therapy on top of optimized sleep (7–8 hours, consistent schedule), resistance training (2–3x/week minimum), adequate protein (often 30–40g per meal), and stress management. The patients who do best treat the medication as one tool in a broader metabolic optimization strategy, not a monotherapy.